arrow
C

C. Benedikt Westphalen

department of medicine iii and comprehensive cancer center
H指数:46
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Navigating rare cancer care: Patient-reported insights into patient journeys, time to diagnosis, decision-making and care coordination from a national cross-sectional study in Germany

导航罕见癌症护理:基于德国一项全国性横断面研究的患者报告见解,涉及患者就医历程、诊断时间、决策制定和护理协调

2025-07-050
PRE
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

罕见内分泌及神经内分泌新生物的精准肿瘤学:CCCMunichLMU分子肿瘤委员会的经验与挑战

2025-06-300
OAAI
Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations

基于临床-公共卫生效用的主流肿瘤学中乳腺癌胚系多基因-panel检测:ESMO精准肿瘤学工作组建议

2025-06-150
PREAI
Real-world outcomes of long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan (nal-IRI) for the Asian cohort of NALLONG study

NALLONG研究中接受脂质体伊立替康(nal-IRI)治疗的亚洲队列中,转移性胰腺导管腺癌(mPDAC)长期生存者的真实世界结局

2024-12-010
PRE
ESMO Recommendations on clinical reporting of genomic test results for solid cancers

ESMO关于实体癌基因组检测结果临床报告的建议

2024-11-010
OAAI
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

2024-11-012
OAAI
Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study

真实世界证据:关于既往接受脂质体伊立替康治疗的转移性胰腺导管腺癌(mPDAC)长期生存者的NALLONG研究

2024-09-010
PRE
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
2024-07-014
OA
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

晚期癌症2024年患者使用下一代测序 (NGS) 的建议: 来自ESMO精密医学工作组的报告

2024-07-0121
OAAI
Relevance of local treatment with curative intent (LT) against metastatic colorectal cancer (mCRC): Findings of a retrospective cohort study at the Comprehensive Cancer Center Munich (CCC MunichLMU)
2024-06-010
PRE